OncoMatch/Clinical Trials/NCT05076942
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
Is NCT05076942 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cisplatin for vulvar cancer.
Treatment: Cisplatin — Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pelvic radiotherapy
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 x 10^9 /l; platelet count ≥ 100 x 10^9 /l
Kidney function
creatinine clearance ≥ 40 ml/min measured by the cockroft gault formula
Liver function
total bilirubin < 1.25 x uln; ast and alt ≤ 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
- Mount Sinai Medical Center · Miami Beach, Florida
- Baystate Medical Center · Springfield, Massachusetts
- Spectrum Health at Butterworth Campus · Grand Rapids, Michigan
- Munson Medical Center · Traverse City, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify